Do Patients with Advanced NSCLC Doing Well on an Immune Checkpoint Inhibitor Reach a Point of Diminishing Returns after a Fixed Duration of Treatment? (BMIC-008)
Sep 13, 2017•7 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West reviews the important, clinically relevant results of the CheckMate-153 trial that asks whether there is a value in continuing an immune checkpoint inhibitor in patients with advanced NSCLC doing well on immunotherapy.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast